| Using four decades of FDA orphan drug designations to describe trends in rare disease drug development: substantial growth seen in development of drugs for rare oncologic … KL Miller, LJ Fermaglich, J Maynard Orphanet Journal of Rare Diseases 16, 265, 2021 | 68 | 2021 |
| A comprehensive study of the rare diseases and conditions targeted by orphan drug designations and approvals over the forty years of the Orphan Drug Act LJ Fermaglich, KL Miller Orphanet Journal of Rare Diseases 18 (1), 163, 2023 | 35 | 2023 |
| Drugs and biologics receiving FDA orphan drug designation: an analysis of the most frequently designated products and their repositioning strategies KL Miller, S Kraft, A Ipe, L Fermaglich Expert opinion on orphan drugs 9 (11-12), 265-272, 2021 | 16 | 2021 |
| Salmonella cervical lymphadenitis in an immunocompetent child exposed to a Snake at an educational exhibit: a case report LJ Fermaglich, JM Routes, PS Lye, SC Kehl, PL Havens Infectious Diseases in Clinical Practice 20 (4), 289-290, 2012 | 5 | 2012 |
| Determining commonalities in the experiences of patients with rare diseases: A qualitative analysis of us food and drug administration patient engagement sessions C Mease, LJ Fermaglich, K Jackler, S Shermer, KL Miller The Patient-Patient-Centered Outcomes Research 17 (1), 25-37, 2024 | 2 | 2024 |
| Common Filing Deficiencies in Abbreviated New Drug Applications Containing Clinical Endpoint Studies LJ Fermaglich, R Chen, CY Kim, EE Chuh, T Thomas, D Shetty, J Lee, ... Therapeutic Innovation & Regulatory Science 53 (1), 81-85, 2019 | 1 | 2019 |
| The Orphan Drug Act and rare cancers: a retrospective analysis of oncologic orphan drug designations and associated approvals from 1983-2022 AV Ipe, LJ Fermaglich, S Kraft, C Mease, T Le, KL Miller Expert Opinion on Orphan Drugs 12 (1), 12-18, 2024 | | 2024 |
| Analysis of the first ten years of FDA’s rare pediatric disease priority review voucher program: designations, diseases, and drug development C Mease, KL Miller, LJ Fermaglich, J Best, G Liu, E Torjusen Orphanet journal of rare diseases 19 (1), 86, 2024 | | 2024 |
| Trends in drug development for amyotrophic lateral sclerosis S Kraft, C Mease, D Jillapalli, LJ Fermaglich, KL Miller Nature Reviews Drug Discovery 23 (2), 99-100, 2024 | | 2024 |
| Ready or Not? A BIOTERRORISM | | 2004 |
Kathleen L. MillerDeputy Director, Division of Science and Public Health Policy, ASPE在 hhs.gov 的电子邮件经过验证
Kathleen L. MillerDeputy Director, Division of Science and Public Health Policy, ASPE在 hhs.gov 的电子邮件经过验证